Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ophthotech Corporation
Subjects will be randomized in a 1:1 ratio to the following dose groups:
* Fovista® 1.5 mg/eye + Lucentis® 0.5 mg/eye
* Fovista® sham + Lucentis® 0.5 mg/eye
Subjects will be treated for a total of 24 months with active Fovista® or sham in combination with Lucentis® with the primary endpoint at 12 months.
Primary Efficacy Endpoint:
The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) from baseline at the month 12 visit.
Safety Endpoints:
Safety endpoints include adverse events, vital signs, ophthalmic variables \[ophthalmic examination, intraocular pressure (IOP), fluorescein angiogram (FA), optical coherence tomography (OCT)\], ECG, and laboratory variables.
Approximately 622 subjects will be randomized into one of the two treatment cohorts (311 patients per dose group).
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects of either gender aged ≥ 50 years
Active subfoveal choroidal neovascularization (CNV) secondary to AMD
Presence of sub-retinal hyper-reflective material (SD-OCT)
You may not be if
Any prior treatment for AMD in the study eye prior to the Day 1 visit, except oral supplements of vitamins and minerals
Any prior intravitreal treatment in the study eye prior to the Day 1 visit, regardless of indication (including intravitreal corticosteroids)
Any intraocular surgery or thermal laser within three (3) months of trial entry. Any prior thermal laser in the macular region, regardless of indication
Subjects with subfoveal scar or subfoveal atrophy are excluded